tbuckley/cabot-search huggingface dataset:
Influenza vaccination in chronic asthma patients. Are more severely ill patients more likely to seek vaccination
Authors: Martin Balzan, Rachelle Assciak, Justine Camilleri, Liam Mercieca, Christopher Sammit, Jesmar Buttigieg, Gabriella Balzan
Journal: European Respiratory Journal (2013)

Introduction: Guidelines for asthma advise annual influenza vaccination.

Aims: To re-assess vaccination rates and attitudes amongst out-patients in hospital clinic for chronic asthma

Method: A questionnaire to patients interviewed in 2011/2 was carried out in 2012/3

Results : Out 146 patients interviewed in 2011/2, 109 patients(78 Female, mean age 53.6, SD 18.0) responded. Vaccination rate was 63.3%, (F70.%. M 45.2%) compared to 54.8% in previous year. 9 (8.3%) patients did not revaccinate while 28.4% did not for either year. 102/109(93.5% reported previous vaccination) and 78(71.6%) vaccinated in at least one year in the last 2. Reasons for newly vaccinated patients(n=18) were doctor’s advice 18 (100%), to protect self 5 (27.8%), to protect family 1 (5.6%), to prevent asthma exacerbations 4(22.2%). For 51 Revaccinated patients 66.7, 39.2, 13.7, 47.1% respectively. Patients vaccinated in 2011/2012 had 0.58 coarses of steroid/patient/year, and 7.3 visits of nebulizer/patient/year while non vaccinated needed 0.18/pt/yr, and 0.65/pt/yr respectively. 13 of 51(25.5%) re-vaccinated patients, and 20/78 (25.6%) of patients vaccinated over two years did so despite reporting previous side effects. Of 31 not vaccinated in either year 22 (71.0%) said this was for fear of side effects. Those Vaccinated in 2011/2(n= 60), 20(33.3%) used beta agonist daily, 14 (23.3%)2-4 times per week, and 26(43.3%) never. For non vaccinated patients in 2011/2 data was 16.3%, 26.5%, 57.12%, respectively.

Conclusion. Re-vaccinated patients gave much more weight to preventing severe asthma attacks and more severely affected patients are likely to vaccinate even in the light of past side effects.
Immunologic Parameters of Ultraviolet Carcinogenesis 2
Authors: Margaret L. Kripke, Michael S. Fisher
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Immunologic Parameters of Ultraviolet Carcinogenesis Get access Margaret L. Kripke, Margaret L. Kripke Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael S. Fisher Michael S. Fisher Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 57, Issue 1, July 1976, Pages 211–215, https://doi.org/10.1093/jnci/57.1.211 Published: 01 July 1976 Article history Received: 04 December 1975 Accepted: 23 January 1976 Published: 01 July 1976
Myc target gene, mina53, as a new prognostic factor for early stage of lung cancer
Authors: Kazutoshi Komiya, Naoko Sueoka, Akemi Satoh, Rika Tomimasu, Takashi Hisatomi, Shinichiro Hayashi, Makoto Tsuneoka, Eisaburo Sueoka
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

4546 

mina53 , a novel gene induced by c-Myc was originally identified by Tsuneoka et al.; it is overexpressed in human colon and esophageal cancer tissues. It has also been reported that patients with high expression of Mina53 have shorter survival periods in cases of esophageal squamous cell carcinoma (ESCC). In addition, reduction of mina53 expression by RNA interference suppressed cell proliferation in colon cancer and ESCC cell lines, suggesting that Mina53 is involved in either cell proliferation or tumor progression. We studied the expression of Mina53 in five lung cancer cell lines and tumor specimens to determine its possible role in lung carcinogenesis: All five lung cancer cell lines showed apparent expression of Mina53 protein, as detected by western blotting. In 6 of 8 lung cancer cases examined, the expression of Mina53 protein was higher in cancerous tissues than in adjacent non-cancerous tissues. Immunohistochemical analysis with monoclonal anti-Mina53 antibody was performed in 106 human lung cancer tissues (56 adenocarcinoma, 32 squamous cell carcinoma, 5 large cell carcinoma, 5 small cell carcinoma and 3 others) obtained from lung cancer patients who had undergone surgery at Saga University Hospital between 1998 and 2000. Sixty-three of 101 (62%) lung cancer specimens showed positive staining in nuclei -especially in nucleoli- with anti-Mina53 antibody, whereas no staining or faint staining was observed in adjacent non-cancerous tissue. In addition, positivity of immunostaining was higher in stage I patients (41 of 58, 71%) compared with more advanced stages (22 of 43, 51%) (p=0.038), suggesting that overexpression of Mina53 is an early event in lung cancer. Concerning clinical parameters, Mina53 positively correlated with immunostaining by c-Myc antibody (p=0.03), whereas no correlation was observed with gender, smoking indices or histological subtypes. In contrast to previous studies on esophageal cancers, patients with negative staining for Mina53 had significantly shorter survival periods than those with positive staining for Mina53 (p=0.004). In addition, subset analysis indicated that the negative staining group had poor prognosis in stageIand for squamous cell carcinoma (p=0.01, p=0.03). Since a majority of the Mina53 negative group were male smokers, it is possible that the carcinogenic processes of Mina53 positive and negative groups are discrete. To clarify the precise role of Mina53 in lung carcinogenesis, functional analysis of Mina53 in the processes of cell growth and transformation is now under investigation.
Reduced oncogenicity of p190 Bcr/Abl F-actin–binding domain mutants
Authors: Nora Heisterkamp, Jan Willem Voncken, Dinithi Senadheera, Ignacio Gonzalez-Gomez, Anja Reichert, Leena Haataja, Arja Reinikainen, Paul K. Pattengale, John Groffen
Journal: Blood (2000)
Study of Methods for Abbreviating Carcinogenicity Bioassays. I. Enhancement of Neoplastic Response by Pretreating With a Potent Carcinogen&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN2"&gt;3&lt;/xref&gt;
Authors: William E. Poel
Journal: JNCI Journal of the National Cancer Institute (1960)

A study was made of the biologic summation of carcinogenic effects induced by serial application of active agents to the skin of mice. Limited pretreatment of the interscapular skin with measured amounts of benzo[a]pyrene in toluene, followed by chronic applications of less potent “test” carcinogenic solutions, reduced the time preceding tumor appearance and augmented the incidence of tumor-bearing animals obtained with either procedure alone. The observed pattern of tumor induction supports the concept that a tumor is a biologic response to the sum of effective carcinogenic stimuli received by a tissue throughout its preneoplastic state. The data suggest the feasibility of summating the effects of calibrated exposures to a potent carcinogen with that of subsequently applied materials of unknown potency as a technique for detecting weak carcinogenic activity or reducing the duration of topical carcinogenesis bioassays.
Abstract 13443: Function Follows Form: Shape and Substrate Stiffness Drive Maturity in Human Cardiomyocytes Differentiated From Pluripotent Stem Cells
Authors: Alexandre Ribeiro, Yen-Sin Ang, Jidong Fu, Renee Rivas, Deepak Srivastava, Beth L Pruitt
Journal: Circulation (2014)

Introduction: Heart function relies on the contractility of its muscle cells (cardiomyocytes). Human pluripotent stem cells (hPSC) can be differentiated into cardiomyocytes (hPSC-CMs). However, while their myogenic maturity increases with time, they do not resemble adult cardiomyocytes in their morphology, structural organization, mechanical output and electrophysiology. The low maturity of hPSC-CMs limits their potential to model, study and treat heart diseases. Hypothesis: Since the organization of sarcomeres regulates the mechanical output of cardiomyocytes, we hypothesized that enhanced sarcomere maturity correlates with the mechanical output of these cells and the physiology of matured cardiomyocytes. Methods: We cultured single hPSC-CMs on 2000 μm2 rectangular protein patterns on polyacrylamide substrates with a modulus of 10 kPa to resemble the morphology of ventricular cardiomyocytes and match healthy adult ventricular stiffness. We infected seeded cells with rAV CAG-LifeAct-Tag RFP to label actin and image sarcomeres in contracting live cells. We estimated forces generated during single-cell contractile events with traction force microscopy and calculated power (force x cell shortening velocity). We varied cell elongation by changing the cell aspect ratio (1:1 to 7:1) and maintaining constant area. We used substrates having stiffness of 6 kPa (embryonic myocardium), 10 kPa (adult) and 35 kPa (infarcted myocardium). Results: Optimized power output was observed in cells with a 7:1 aspect ratio. The size, organization and dynamics of sarcomeres in these elongated hPSC-CMs are more mature. Optimized power output was observed in cells with a 7:1 aspect ratio. The power generated by hPSC-CMs on 35 kPa substrates was significantly reduced, while reduced variations in the power output across different aspect ratios was observed in 6 kPa. Forces generated by patterned hPSC-CMs were related to the organization, dynamics and size of sarcomeres. Electrophysiological parameters closer to that of mature cardiomyocytes were also observed with patch-clamp measurements in these hPSC-CMs with mature sarcomere organization. Conclusions: Stiffness and shape contribute to the structural and electrophysiological maturation of hPSC-CMs.
Reconstruction of an Extracardiac Aortocoronary Collateral and Simulation of Selective Angiography With Multidetector-Row Computed Tomography
Authors: Akira Kasamatsu, Tomofumi Takaya, Shumpei Mori, Kazuhiro Kashio, Hachidai Takahashi, Tatsuro Ito, Sachiko Takamine, Sei Fujiwara, Tatsuya Nishii, Atsushi K. Kono, Toshiro Shinke, Ken-ichi Hirata
Journal: Circulation (2015)
Abstract 4535: Inhibition of cell proliferation by (R,R')-4′-methoxy-1-naphthylfenoterol in breast cancer cell lines
Authors: Rajib K. Paul, Artur Wnorowski, Michel Bernier, Irving W. Wainer
Journal: Cancer Research (2014)

Abstract (R,R')-4′-methoxy-1-naphthylfenoterol (MNF) is a bitopic ligand that acts as an agonist of the β2-adrenergic receptor and an antagonist of the orphan G-protein-coupled receptor GPR55. Activation of GPR55 is pro-oncogenic through cannabinoid-related signal transduction and MNF treatment inhibits proliferation of different tumor cell lines, representing cancers of the liver, pancreas and brain. Of significance, MNF exerts antitumor activity in a xenograft glioma model in nude mice. In the current study, the anti-proliferative response mediated by MNF has been examined in human breast cancer cell lines. In this study, MCF-7 and MDA-MB-231 cells were screened for the presence of epidermal growth factor receptor (EGFR) and GPR55 proteins by Western blotting. The EGFR in such cancer cells plays a key role in the control of growth and proliferation. When compared to MCF-7 cells, MDA-MB-231 cells contained high levels of EGFR and GPR55 and showed exquisite sensitivity to MNF as evidenced by the significant reduction in constitutive phosphorylation of the extracellular signal-regulated kinase (ERK1/2), with an IC50 of 0.08 nM. [3H]-Thymidine incorporation assay was performed and revealed that MNF elicited a 2-fold higher growth inhibition in MDA-MB-231 cells as compared to MCF-7 cells (50% vs. 24.9% inhibition at 10 µM of MNF; p&amp;lt;0.001). Evidence for the altered expression and/or signaling pathway activation triggered by EGFR and GPR55 in response to MNF will be presented. We conclude that MDA-MB-231 cells represent a suitable model for the study of possible crosstalk between two classes of pro-oncogenic cell surface receptors and the analysis of MNF as novel therapeutic agent for the management of cancer. This work was supported entirely by the Intramural Research Program of the National Institute on Aging, NIH. Citation Format: Rajib K. Paul, Artur Wnorowski, Michel Bernier, Irving W. Wainer. Inhibition of cell proliferation by (R,R')-4′-methoxy-1-naphthylfenoterol in breast cancer cell lines. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4535. doi:10.1158/1538-7445.AM2014-4535
Portrait of Louise-Antoinette Feuardent
Authors: M. Therese Southgate
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P300: Circulating MicroRNAs Associated with Glycemic Impairment and Progression in Asian Indians
Authors: Elena Flowers, Bradley E Aouizerat, Meghana Gadgil, Alka M Kanaya
Journal: Circulation (2015)

Introduction: Asian Indians experience a high incidence of type 2 diabetes (T2D), but factors associated with glycemic progression from normal to pre-diabetes to diabetes in this population are not fully understood. Circulating microRNAs (miRs) appear to be implicated in T2D etiology in other racial groups. Hypothesis: Circulating miRs are associated with glycemic impairment and progression in participants in the Metabolic Syndrome and Atherosclerosis in South Asians Living in America (MASALA) study. Methods: Participants were 128 Asian Indians age 45-84 years without cardiovascular disease and not taking diabetes medications. Oral glucose tolerance tests were performed at baseline and after 2.5 years. Glycemic progression was defined as (1) progression from normal to impaired fasting glucose (fasting glucose 100-125 mg/dl) or diabetes (2-hour glucose ≥200 mg/dl, fasting glucose ≥126 mg/dl or diabetes medication use) or (2) from impaired glucose tolerance (2-hour glucose 140-199 mg/dl) to diabetes (see above). Circulating miRs from plasma collected during the enrollment visit were measured using the Firefly Circulating microRNA assay. Unadjusted and multivariate-adjusted logistic regression models were created to determine the relationship between circulating miRs and glycemic impairment and progression. Results: The mean age was 57 ± 8 years and 48% (n=62) were men. Glycemic impairment was present in 57% (n=73) at baseline. The prevalence of glycemic progression after 2.5 years was 24% (n=23). Two circulating miRs were associated with glycemic impairment and seven with glycemic progression after 2.5 years (see Table). Conclusions: To our knowledge, this is the first study to investigate circulating miRs associated with glycemic impairment in the high risk Asian Indian racial group. Individual miRs were significantly associated with both glycemic impairment and glycemic progression. Further studies are needed to determine whether miR(s) might be useful clinical biomarkers for incident T2D in this population.
MULTIPLE MYELOMA WITH SPINAL CORD COMPRESSION AS THE INITIAL FINDING
Authors: L J SNYDER, S K WILHELM
Journal: Annals of Internal Medicine (1948)

Case Reports1 June 1948MULTIPLE MYELOMA WITH SPINAL CORD COMPRESSION AS THE INITIAL FINDINGLEOPOLD J. SNYDER, M.D., SEYMOUR K. WILHELM, M.D.LEOPOLD J. SNYDER, M.D.Search for more papers by this author, SEYMOUR K. WILHELM, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-28-6-1169 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptPlasma cell myeloma causing spinal cord compression has occasionally been reported. Klemme1in 1933 reported five cases which he had observed in a three year period. Paul and Pohle2found 14 cases of myeloma of the spine in 45 cases of solitary myeloma of bone, whereas Pasternack and Waugh3noted that four of 30 cases of solitary myeloma of bone occurred in the spine. Denker and Brock4point out that many myelomas begin in a vertebral body and "announce their presence by compression of the cord." These authors go on to state that "typically the case is in a person...Bibliography1. KLEMME RM: Plasma cell myelomas causing spinal cord compression: report of 5 cases, South. Med. Jr., 1933, xxvi, 692. CrossrefGoogle Scholar2. PAULPOHLE LWCA: Solitary myeloma of bone, Radiology, 1944, xxxv, 651. Google Scholar3. PASTERNACKWAUGH JGRL: Solitary myeloma of bone, Ann. Surg., 1939, cx, 427. CrossrefGoogle Scholar4. DENKERBROCK PGS: The generalized and vertebral forms of myeloma: their cerebral and spinal complications, Brain, 1934, lvii, 291. CrossrefGoogle Scholar5. WRIGHT AD: Solitary plasma-celled myeloma of the vertebral body causing paraplegia, Proc. Roy. Soc. Med., 1937, xxx, 931. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Eloise, Michigan*Received for publication January 13, 1947.From the Medical Department of the Wayne County General Hospital and Infirmary, Eloise, Michigan. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySpinal Cord Compression in MyelomaRaumbeengende Prozesse im Spinalkanal (einschließlich Angiome und Parasiten)Metastatic neoplasms of the vertebral column producing compression of the spinal cordSpinal Cord Compression Caused by Plasma-Cell TumoursCompressões medicares provocadas por mielomas vertebraisDiagnostic and Therapeutic Aspects of Multiple Myeloma 1 June 1948Volume 28, Issue 6Page: 1169-1177KeywordsBoneMultiple myelomaMyelomaSpinal cordSpine ePublished: 1 December 2008 Issue Published: 1 June 1948 PDF downloadLoading ...
In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis
Authors: Khalid Shah, Ching-Hsuan Tung, Xandra O. Breakefield, Ralph Weissleder
Journal: Molecular Therapy (2005)

Therapeutic proteins with specific effector functions play an increasingly important role in drug therapy. For example, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) predominantly kills cancer cells, while sparing normal cells. Here, we report the use of a secreted version of TRAIL as a therapeutic protein that induces apoptosis and kills surrounding cells in vivo, thus resulting in the dramatic reduction of glioma burden in mouse tumor models. Using a caspase-3-activatable aminoluciferin, we were able to show the induction of apoptosis specifically in S-TRAIL vector-infected gliomas. We also show that S-TRAIL-mediated apoptosis and resulting changes in tumor burden can be imaged in the same animal by dual-substrate bioluminescence imaging. The use of S-TRAIL as a therapeutic protein and the ability to image noninvasively both apoptosis and any other cellular events in real time have important clinical implications.
Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C
Authors: Borbala Mifsud, Filipe Tavares-Cadete, Alice N Young, Robert Sugar, Stefan Schoenfelder, Lauren Ferreira, Steven W Wingett, Simon Andrews, William Grey, Philip A Ewels, Bram Herman, Scott Happe, Andy Higgs, Emily LeProust, George A Follows, Peter Fraser, Nicholas M Luscombe, Cameron S Osborne
Journal: Nature Genetics (2015)
Abstract 4196: An RNA aptamer-based approach for human glioma treatment
Authors: Simona Camorani, Carla L. Esposito, Silvia Catuogno, Paola Amero, Anna Rienzo, Gennaro D. Vita, Gerolama Condorelli, Vittorio de Franciscis, Laura Cerchia
Journal: Cancer Research (2014)

Abstract Gliomas are the most common primary central nervous system tumors with a dismal prognosis. Despite recent advances in surgery, radiotherapy, and chemotherapy, current treatment regimens have a modest survival benefit. Due to a combination of its complex phenotype and organ-specific clinical manifestations, efforts to refine glioma treatment with targeted therapies have largely been frustrated. Hence, finding specific ligands capable of detecting and measuring the altered pattern of gene expression and to discriminate between different tumor phenotypes, is a strategic and plausible objective for the diagnosis and therapy of glioma. To date, antibody-based approaches have been developed for in vivo applications but, in most cases, they show toxicity in vivo and do not reach adequate sensitivity. Thanks to their unique characteristics (low size, good affinity for the target, no immunogenicity, chemical structures that can be easily modified to improve their in vivo applications), single-stranded nucleic acid ligand molecules, named aptamers, represent a valid alternative to antibodies for in vivo targeted recognition as therapeutics or delivery agents for nanoparticles, small interfering RNAs, chemotherapeutic cargos and molecular imaging probes. By applying cell-SELEX on cancer cells we have generated and characterized different nuclease resistant 2′fluoro-pyrimidines RNA aptamers as high affinity ligands and inhibitors of human receptor tyrosine kinases (RTKs) with a crucial role in glioma, including EGFR, EGFRVIII, EphB3, Axl and PDGFRβ. All the aptamers are able to efficiently and specifically inhibit tumor growth in cell based assays and in animal models of human glioma. Further, some of these aptamers strongly cooperates in inducing inhibition of tumor growth thus providing the basis for further development of antitumor combination therapies. Citation Format: Simona Camorani, Carla L. Esposito, Silvia Catuogno, Paola Amero, Anna Rienzo, Gennaro De Vita, Gerolama Condorelli, Vittorio de Franciscis, Laura Cerchia. An RNA aptamer-based approach for human glioma treatment. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4196. doi:10.1158/1538-7445.AM2014-4196
Abstract 52: Purpose in Life and its Relationship to All-Cause Mortality and Cardiovascular Events: A Meta-Analysis
Authors: Randy Cohen, Chirag Bavishi, Alan Rozanski
Journal: Circulation (2015)

Background: Purpose in life is a component of psychological well-being and has been associated in some studies with reduced mortality. To assess the net impact of purpose in life on cardiovascular events, we performed a meta-analysis of all relevant studies. Methods: A systemic search was undertaken to identify all studies investigating the relationship between purpose in life, all-cause mortality and cardiovascular events. Unadjusted and adjusted effect estimates were pooled using random effects model. Results: 10 prospective studies (n =137,142, mean follow-up 8.5 years) were included in the analysis. A significant association was observed between having a higher purpose in life and reduced all-cause mortality [adjusted pooled relative risk (RR): 0.77 (CI: 0.69-0.86), p<0.001] and cardiovascular events [adjusted RR: 0.81 (CI: 0.73-0.90), p<0.001]. Subgroup analyses yielded similar results. Conclusions: Possessing a high sense of purpose in life is associated with a reduced risk for all-cause mortality a...